Company attributes
Other attributes
CSL Behring is a biotechnology leader that focuses on serving patients’ needs. Scientists at CSL Behring use modern technologies to build and deliver innovative therapies used for the treatment of serious and rare diseases, including autoimmune and immunodeficiency diseases, hereditary and acquired bleeding disorders, hereditary angioedema (HAE), chronic inflammatory demyelinating polyneuropathy (CIDP), and Alpha 1 antitrypsin deficiency, as well as critical care and transplantation.
The company works with plasma donors, patient groups, researchers, physicians, nurses, pharmacists and home healthcare companies to aid quality care, enhance patient access to care, expand educational outreach efforts, and affect public healthcare policy. The company offers a wide range of products in the industry and it continues to introduce new rare-disease innovations for addressing unmet medical needs or improving current treatments.
The company's portfolio of medicines includes a broad range of recombinant and plasma-derived products for the treatment of bleeding disorders, immune deficiencies, and chronic inflammatory demyelinating polyneuropathy, as well as Alpha 1 Antitrypsin Deficiency and hereditary angioedema.
